Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Significant association to BC predisposition was observed for <i>ATM, PALB2, TP53, RAD51C</i> and <i>CHEK2</i> PVs.
|
31300551 |
2020 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Eight PVs in ATM, BRCA2 (x2), PALB2, RAD51D, BRIP1, and MUTYH (x2) were identified in 7 of 44 individuals with breast cancer (15.9%, 95% CI: 7-30%), whereas none were identified in healthy controls (p = .01).
|
31575519 |
2020 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis included nuclear exclusion of FOXO3 as a marker of follicle activation, γH2AX as a marker of DNA damage, meiotic recombination 11 (MRE11), ataxia telangiectasia mutated (ATM), Rad51, breast cancer susceptibility 1 (BRCA1) and breast cancer susceptibility 2 (BRCA2) as DNA repair factors.
|
30521029 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Oxidized ATM-mediated glycolysis enhancement in breast cancer-associated fibroblasts contributes to tumor invasion through lactate as metabolic coupling.
|
30799198 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Enrichment of pathogenic variants were identified in 4 non-BRCA genes associated with breast cancer risk: ATM (odds ratio [OR], 2.97; 95% CI, 1.67-5.68), CHEK2 (OR, 2.19; 95% CI, 1.40-3.56), PALB2 (OR, 5.53; 95% CI, 2.24-17.65), and MSH6 (OR, 2.59; 95% CI, 1.35-5.44).
|
30128536 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings identified a novel mutation that disrupts ATM function, conferring to breast cancer risk.
|
31160347 |
2019 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Tumours with low ATM or high ATR levels in conjunction with MYC overexpression also have worse overall breast cancer-specific survival (BCSS) (p value < 0.05).
|
30746633 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Loss of one or both alleles of ATM results in an increased risk of cancer development, particularly haematopoietic cancer and breast cancer in both humans and mouse models.
|
31565865 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These results do not support an impact of ATM rs1801516 on late skin reactions of radiotherapy for breast cancer, nevertheless further large studies are still required for conclusive evidences.
|
31756226 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
After Bonferroni correction (P ≤ 1.3 × 10-5), the strongest associations were detected in five pathways and gene sets, including maturity-onset diabetes of the young, regulation of beta-cell development, role of epidermal growth factor (EGF) receptor transactivation by G protein-coupled receptors in cardiac hypertrophy pathways, and the Nikolsky breast cancer chr17q11-q21 amplicon and Pujana ATM Pearson correlation coefficient (PCC) network gene sets.
|
30541042 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Intracellular citrate accumulation by oxidized ATM-mediated metabolism reprogramming via PFKP and CS enhances hypoxic breast cancer cell invasion and metastasis.
|
30850587 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Most data were available for DDR panels (n=12 studies), ataxia telangiectasia mutated (ATM; n=13), breast cancer susceptibility gene (BRCA)1 (n=14) and BRCA2 (n=20).
|
31322208 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline DNA from 1054 BRCA-mutation-negative Hispanic women with hereditary BC (BC diagnosed at age <51 years, bilateral BC, breast and ovarian cancer, or BC diagnosed at ages 51-70 years with ≥2 first-degree or second-degree relatives who had BC diagnosed at age <70 years), 312 local controls, and 887 multiethnic cohort controls was sequenced and analyzed for 12 known and suspected, high-penetrance and moderate-penetrance cancer susceptibility genes (ataxia telangiectasia mutated [ATM], breast cancer 1 interacting protein C-terminal helicase 1 [BRIP1], cadherin 1 [CDH1], checkpoint kinase 2 [CHEK2], nibrin [NBN], neurofibromatosis type 1 [NF1], partner and localizer of BRCA2 [PALB2], phosphatase and tensin homolog [PTEN], RAD51 paralog 3 [RAD51C], RAD51D, serine/threonine kinase 11 [STK11], and TP53).
|
31206626 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, overall survival and recurrence-free survival analysis revealed the close associations of the expression of GATA3, NCOR1, CDH1, and ATM with survival of BC patients.
|
30883028 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D.
|
30552672 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Not only AT patients, but also certain ATM heterozygous mutation carriers show a significantly reduced life expectancy due to cancer and ischemic heart disease; in particular, female carriers having particular alleles have an increased risk of breast cancer.
|
31443742 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BOADICEA incorporates the effects of truncating variants in BRCA1, BRCA2, PALB2, CHEK2, and ATM; a PRS based on 313 single-nucleotide polymorphisms (SNPs) explaining 20% of BC polygenic variance; a residual polygenic component accounting for other genetic/familial effects; known lifestyle/hormonal/reproductive RFs; and mammographic density, while allowing for missing information.
|
30643217 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PP2Cδ inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer.
|
31663018 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We therefore investigated the spectrum and clinical characteristics of ATM germline mutations in Chinese breast cancer patients.
|
30607632 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 or BRCA2 mutations were found in 7.3% of the subjects, 6.3% had a mutation in other breast cancer genes (PALB2, CHEK2, ATM, and BARD1), and 1.6% had mutations in genes not associated with breast cancer.
|
30933323 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, the synthetically lethal interaction between PTEN and ATM in breast cancer has not been reported.
|
29522753 |
2018 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer screening for ATM mutations carriers and referral to international experts in two undiagnosed patients were arranged.
|
29524103 |
2018 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In haplotype analysis, haplotypes A-C-G-G (in order of rs189037, rs3092856, rs1801516 and rs373759) and A-C-A-A in ATM gene were significantly associated with 1.98-fold and 6.04-fold increased risk of breast cancer (95% CI: 1.36-2.90 and 1.65-22.08, respectively).
|
29691986 |
2018 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we hypothesize a role of variants in the ATM, H2AFX and MRE11 genes in determining breast cancer (BC) susceptibility.
|
29678143 |
2018 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that Triptolide specifically chemosensitizes breast cancer cells to Doxorubicin prior to apoptosis initiation through downregulating ATM expression and inhibiting DNA damage response.
|
29500880 |
2018 |